Latest News

Trial investigator Claudia R. Morris, MD, said substantial variation in pain phenotypes, treatment practices, and trial end points may offer broader lessons for future acute sickle cell disease research.

Both virtual and in-person interviews have their benefits.

Time-to-vaccination data from a large diabetes cohort reveal delayed, incomplete uptake of pneumococcal vaccination, with age and citizenship emerging as the strongest predictors.

The phase 3 findings support MR-107A-02's potential as a nonopioid option for certain patients with moderate to severe acute pain.

Five "essential" outcomes, including medication error and adherence, should anchor every pharmacist intervention study in chronic kidney disease.

Melissa Seifert, PharmD, of UPMC Health Plan, explains how managed care pharmacists guide DMT selection and address adherence barriers in patients with MS.

A subsequent dispute between state and federal officials over the deaths' classification has thrust the state into the center of a national vaccine policy fight.

A multicohort study finds divergent complication patterns and raises the prospect that millions are being treated for the wrong mechanism.

This FAQ describes what oncology pharmacists should know ahead of Gynecologic Cancer Awareness Month in September.

August 2026 brought major oncology advances, including new FDA approvals and pivotal phase 3 data that expanded targeted, immune-based, and personalized treatment strategies.

August 2026 brought first-in-class approvals in multiple myeloma, warm autoimmune hemolytic anemia, and polycythemia vera alongside important findings involving bispecific antibodies, sickle cell pain, and infection risk.

The approval makes ustekinumab the first non-TNF-alpha monoclonal antibody available for both major forms of pediatric inflammatory bowel disease (IBD).

Rusfertide gives adults with polycythemia vera a first-in-class option to cut phlebotomy dependence and control hematocrit.

Suzetrigine postoperative pain data grows, but buprenorphine access gaps persist; naloxone patch and sickle cell pain trial reshape nonopioid care.

From enlicitide to Lp(a)-lowering siRNAs, a look at the add-on therapies helping high-risk patients reach stricter LDL targets below 55 mg/dL.

Tarlatamab targets DLL3 in lung cancer; learn step-up dosing, CRS/ICANS monitoring, and pharmacy tips to keep patients safely on therapy.

IPD survivors face years of sharply elevated recurrence risk, yet vaccination remains low.

Real-world data show sustained tirzepatide use offset its cost by 12 months in adults older than 55 years, with fewer hospital and ED visits.

Bictegravir/lenacapavir (Bixlenvo) offers the first single-tablet option for many patients with HIV currently receiving complex antiretroviral regimens.

Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.

The updated formula targets the JN. 1-lineage XFG variant and begins shipping immediately to pharmacies, hospitals, and clinics nationwide.